Ocu-Xyl ™
Ocu-Xyl ™ - Image 2
Ocu-Xyl ™ - Image 3

Ocu-Xyl ™

    $95.00

    Ocu-Xyl™ is a supplement that promotes eye health, addressing concerns like glaucoma and age-related macular degeneration (AMD). These two conditions are often referred to as “Alzheimer’s disease of the eye” due to their similarities with Alzheimer’s disease. Specifically, they share pathological traits, such as the accumulation of toxic proteins like beta-amyloid, which can harm retinal cells and lead to vision impairment or blindness.

    Category:

      Glaucoma

      Supporting healthy retinal function is crucial for maintaining good vision, as it plays a key role in everyday functionality. Glaucoma, one of the leading causes of blindness, affects:

      • 1 in 200 people under 50 years old.
      • 1 in 10 people over 80 years old.

      Types of Glaucoma

      1. Open-angle glaucoma:
        • Accounts for 90% of cases in the U.S..
      2. Closed-angle glaucoma:
        • Accounts for less than 10% of cases in the U.S..
        • Can comprise up to 50% of cases in Asian countries.

      Scientific Findings

      • Beta-amyloid (Aβ) deposits in the retina contribute to retinal ganglion cell death, a key factor in glaucoma development.
      • Strategies for prevention:
        • Removing aggregated Aβ.
        • Preventing further accumulation.
        • Protecting retinal cells from Aβ toxicity.
        • Repairing damaged retinal cells.
        • Improving retinal cell viability.

      Age-related Macular Degeneration (AMD)

      AMD is another leading cause of blindness, particularly in adults over 50. It is characterized by:

      • Drusen deposits, which lead to:
        • Retinal pigmented epithelium (RPE) atrophy.
        • Disruption of the epithelial barrier.
        • Photoreceptor death in the macula.

      Statistics

      • Signs of AMD appear in:
        • 10% of people aged 66–74.
        • 30% of people aged 75–85.

      Forms of AMD

      1. Dry AMD:
        • Drusen accumulates, causing photoreceptor loss (rods and cones).
      2. Wet AMD:
        • New blood vessels grow behind the retina, detaching it and causing acute vision loss.
        • Found in 10% of AMD cases but is more severe.

      Scientific Findings

      • Excess Aβ deposits in the drusen are associated with AMD, glaucoma, and Alzheimer’s disease.
      • Reducing Aβ accumulation could potentially prevent AMD development.

      How Ocu-Xyl™ Works

      Ocu-Xyl™ addresses retinal health by:

      1. Removing Aβ aggregates.
      2. Preventing Aβ accumulation.
      3. Protecting retinal cells from Aβ toxicity.
      4. Repairing damaged retinal cells.
      5. Enhancing retinal cell viability.

      Supplement Fact

      Serving Size 1 capsule (Approx. ~760 mg)

      Turmeric (Curcuma longa) ~250mg
      Ginger (Zingiber officinale) ~220 mg
      Cinnamon (Cinnamomum zeylanicum) ~100mg
      Scutellaria baicalensis ~75mg
      Piper nigrum ~60mg
      Calendula officinalis ~55mg

      *Daily Values (%DV) are not established.

      Ingredients:
      Turmeric, Ginger, Cinnamon, S. baicalensis, P. nigrum, C. officinalis, vegetable capsule

      Suggested Use:
      Adults – As a dietary supplement, take 1~2 capsules two times daily, preferably with a meal.

      Warnings:
      Pregnant women and MAO inhibitor users should not take this product. Use of this product is not intended to replace regular visit to your physician. Keep this product out of reach of children.

      Important:
      Tamper evident seal under cap. Do not use if protective seal is broken or missing. Store at room temperature, tightly closed. Avoid excessive heat and humidity.

      Free of:
      Sugar, salt, preservatives, artificial flavor or color, starch, milk, egg, corn, wheat, yeast, soy.

      This is a specially processed product made from turmeric, ginger, cinnamon, P. nigrum, S. baicalensis, and C. officinalis using GLL Corp’s proprietary technology. This product contains patent protected compounds and antioxidants GXC-00105, GXC-00124, GXC-00242, GXC-00273, GXC-00288,
      GXC-00312 etc. that have shown to protect cells in the eyes from bête-amyloid, which has been identified as one of the culprits of retinal cell atrophy-related diseases

      The formulation, and the claims thereof are exclusive properties of the product

      Patents:
      U.S. 6,887,898; 7,279,501; 7,282,523; 7,572,829; 7,728,043 and other patents pending.

      This is a product of GLL Corp.

      Distributed by:
      Core LifeSource, Inc., Rolling Meadows, IL 60008

      MADE IN USA.

      *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.